Drug Trial Radar · NCT04077099
A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
95
Actual
Start
Jan 7, 2020
Primary completion
Jul 6, 2027
Study completion Jul 6, 2027
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Sep 4, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate REGN5093 for the treatment of Non-Small Cell Lung Cancer (NSCLC) with MET alteration. The main purpose of this study is to determine the safety, tolerability, and effectiveness of REGN5093. The study has two phases. The main goal of Phase 1 is to determine a safe dose(s) of REGN5093. The main goal of phase 2 of the study is to use the REGN5093 drug dose(s) found in Phase 1 to see how well REGN5093 works to shrink tumors. The study is looking at several other research questions, including: * Side effects that may be experienced by people taking REGN5093 * How REGN5093 works in the body * How much REGN5093 is present in the blood * To see if REGN5093 works to reduce or delay the progression of cancer * How long it takes REGN5093 to work in the body
Conditions
- NSCLC
Interventions
REGN5093Drug
Intravenous (IV) infusion. There will be a series of dose escalation cohorts followed by an expansion phase.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients with Dose Limiting Toxicities (DLTs)Time frame: Up to 21 days
- Incidence and severity of treatment-emergent adverse events (TEAEs)Time frame: Through study completion, an average of 12 years
- Incidence and severity of adverse events of special interest (AESIs)Time frame: Through study completion, an average of 12 years
- Incidence and severity of serious adverse events (SAEs)Time frame: Through study completion, an average of 12 years
- Incidence and severity of grade ≥3 laboratory abnormalitiesTime frame: Through study completion, an average of 12 years
- REGN5093 concentrations in serum over timeTime frame: Through study completion, an average of 12 years
- Objective response rate (ORR) per RECIST 1.1Time frame: Through study completion, an average of 12 years
Locations
29 sites in 3 countries. Site status is shown where the registry gives one.
University of California Irvine Medical Center - Bldg 56, RT81, Rm 241
Orange, California
Georgetown University Medical Center
Washington D.C., District of Columbia
Moffitt Cancer Center - McKinley Drive
Tampa, Florida
Dana Farber Harvard Cancer Center Consortium
Boston, Massachusetts
Icahn School of Medicine at Mount Sinai
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University of Pittsburgh UPMC - Clinical Research Services
Pittsburgh, Pennsylvania
The University of Texas MD Anderson Cancer Center
Houston, Texas
Centre Hospitalier Universitaire de Grenoble
Grenoble, France
Centre Hospitalier Regional Universitaire (CHRU) Montpellier Arnaud de Villeneuve
Montpellier, France
Centre Hospitalier Universitaire de Rennes - Hopital Pontchaillou
Rennes, Bretange, France
Institut Bergonie
Bordeaux, New Aquitaine, France
Centre Francois Baclesse (CFB)
Caen, Normandy, France
Pusan National University Hospital
Busan, South Korea
Severance Hospital Yonsei University Health System
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seol St. Mary's Hospital
Seoul, South Korea
Boramae Medical Center
Seoul, South Korea
Korea University Guro Hospital
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
National Cancer Center
Gyeonggi-do, Gyeonggi-do, South Korea
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
The Catholic University Of Korea St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea
Ajou University Hospital
Suwon, Gyeonggi-do, South Korea
Haeundae Paik Hospital
Pusan, Gyeongsangnam-do, South Korea
Chonnam National University Hwasun Hospital
Hwasun, Jeollanam-do, South Korea
Gachon University Gil Medical Center
Incheon, Namdong-gu, South Korea
Chungbuk National University Hospital
Cheongju-si, North Chungcheong, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.